CATHERINE BARTON: Open Payments
NPI 1528598067 · KISSIMMEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,530 in 40 payments from 13 companies in 2025. Trend: 2023 $1,651 · 2024 $923 · 2025 $1,530
Food & beverage: $1,530
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $364 |
| Alkermes, Inc. | 7 | $287 |
| Neurocrine BioSciences, Inc. | 2 | $154 |
| Axsome Therapeutics, Inc. | 3 | $151 |
| ABBVIE INC. | 4 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Janssen Pharmaceuticals, Inc | 2 | $65 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
Products named: CAPLYTA, LYBALVI, INGREZZA, Auvelity, VRAYLAR, FANAPT, ARISTADA, COBENFY.
Industry payments across FL — which companies pay providers there.
